²²⁵Ac-RAX104 / RadAlliance Therapeutics - LARVOL DELTA

²²⁵Ac-RAX104: A novel PSMA-targeted radioligand optimized for actinium-225 demonstrates enhanced tumor retention and superior efficacy (AACR 2026) - "Although the clinical success of ¹⁷⁷Lu-PSMA-617 (Pluvicto) has established PSMA-targeted radioligand therapy (RLT) as an effective treatment for metastatic castration-resistant prostate cancer (mCRPC), emerging clinical evidence indicates that ²²⁵Ac-based RLT can deliver even greater therapeutic efficacy owing to the high linear energy transfer of α-particles and the radionuclide's 9.92-day physical half-life. Collectively, these results demonstrate that ²²⁵Ac-RAX104 achieves optimal kinetic alignment with ²²⁵Ac's physical decay and biological action, delivering enhanced tumor exposure and potent therapeutic efficacy at one-fifth the dose of ²²⁵Ac-PSMA-617. These findings support ²²⁵Ac-RAX104 as a promising next-generation PSMA α-radioligand therapy with the potential to improve outcomes in mCRPC and warrant further clinical development."

Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor